Takbo Group Holdings Limited (8436.HK)
HKD 0.2
(0.0%)
HKD 0.2
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 25.8 Million HKD | -17.89% |
| 2022 | 11.14 Million HKD | 36.25% |
| 2021 | 14.81 Million HKD | -49.97% |
| 2020 | 30.3 Million HKD | -29.59% |
| 2019 | 45.64 Million HKD | 13.4% |
| 2018 | 40.26 Million HKD | 254.38% |
| 2017 | 11.36 Million HKD | -39.74% |
| 2016 | 19.27 Million HKD | 4.76% |
| 2015 | 18.39 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.28 Million HKD | 112.35% |
| 2024 Q2 | 4.6 Million HKD | 257.06% |
| 2023 Q2 | 7.26 Million HKD | 283.66% |
| 2023 Q3 | 27.97 Million HKD | 285.17% |
| 2023 Q4 | 14.41 Million HKD | -48.46% |
| 2023 Q1 | -3.95 Million HKD | 57.67% |
| 2023 FY | - HKD | -17.89% |
| 2022 Q2 | -773 Thousand HKD | 33.99% |
| 2022 FY | - HKD | 36.25% |
| 2022 Q4 | -9.34 Million HKD | -140.17% |
| 2022 Q3 | 23.25 Million HKD | 3107.89% |
| 2022 Q1 | -1.17 Million HKD | 82.78% |
| 2021 FY | - HKD | -49.97% |
| 2021 Q4 | -6.79 Million HKD | -158.35% |
| 2021 Q3 | 11.65 Million HKD | 2180.71% |
| 2021 Q2 | -560 Thousand HKD | -133.59% |
| 2021 Q1 | 1.66 Million HKD | 117.89% |
| 2020 Q3 | 21.14 Million HKD | 104.18% |
| 2020 Q2 | 10.35 Million HKD | 657.43% |
| 2020 FY | - HKD | -29.59% |
| 2020 Q1 | 1.36 Million HKD | -13.26% |
| 2020 Q4 | -9.32 Million HKD | -144.08% |
| 2019 Q4 | 1.57 Million HKD | -94.72% |
| 2019 Q3 | 29.82 Million HKD | 962.97% |
| 2019 FY | - HKD | 13.4% |
| 2019 Q2 | 2.8 Million HKD | -43.92% |
| 2019 Q1 | 5 Million HKD | -49.52% |
| 2018 Q2 | -3.42 Million HKD | -231.08% |
| 2018 Q4 | 9.91 Million HKD | -67.35% |
| 2018 FY | - HKD | 254.38% |
| 2018 Q3 | 30.35 Million HKD | 987.63% |
| 2018 Q1 | 2.6 Million HKD | 126.01% |
| 2017 Q3 | 25.17 Million HKD | 2259.23% |
| 2017 Q1 | -6.48 Million HKD | 23.9% |
| 2017 FY | - HKD | -39.74% |
| 2017 Q4 | -10.03 Million HKD | -139.85% |
| 2017 Q2 | 1.06 Million HKD | 116.47% |
| 2016 Q4 | -8.51 Million HKD | -142.71% |
| 2016 FY | - HKD | 4.76% |
| 2016 Q3 | 19.93 Million HKD | 0.0% |
| 2015 FY | - HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Natural Beauty Bio-Technology Limited | 22.91 Million HKD | -12.622% |
| Innovative Pharmaceutical Biotech Limited | 317.74 Million HKD | 91.879% |
| China Overseas Nuoxin International Holdings Limited | 2.02 Million HKD | -1171.759% |
| Prosperous Future Holdings Limited | -19.68 Million HKD | 231.078% |
| Huasheng International Holding Limited | 19.67 Million HKD | -31.131% |
| Fourace Industries Group Holdings Limited | 61.52 Million HKD | 58.059% |
| Evergreen Products Group Limited | 140.78 Million HKD | 81.671% |
| EC Healthcare | 737.83 Million HKD | 96.503% |
| Ming Fai International Holdings Limited | 211.83 Million HKD | 87.819% |
| Blue Moon Group Holdings Limited | 656.37 Million HKD | 96.069% |
| SuperRobotics Holdings Limited | -7.39 Million HKD | 448.75% |
| Hyfusin Group Holdings Limited | 154.18 Million HKD | 83.264% |